Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > Nitric Oxide: The Missing Factor in COVID-19 Severity?
View:
Post by Red~One on Sep 20, 2022 10:53pm

Nitric Oxide: The Missing Factor in COVID-19 Severity?

"What started as an observation of the correlation between the severity of COVID-19 symptoms associated with old age, and the age-related decline of NO levels, has now tied low NO levels to all major high-risk groups of COVID-19 infection. This overwhelming amount of correlation data and the sound biochemical reasoning behind low NO levels and the corresponding conditions that increase COVID-19 infection severity as well as the symptomatology exclusive to COVID-19, the successful utilization of NO gas as a therapeutic option, and the emergence of evidence tying NOx to COVID-19 severity, make further research on the matter warranted."

3.2. Nitric Oxide and COVID-19 Patient Outcomes: What Does the Evidence Suggest?

"Since the conception of the authors’ hypothesis that COVID-19 severity and pathology is correlated to NO bioavailability and successful treatment and prevention options can be developed manipulating this pathway, clinical evidence supporting this hypothesis has emerged. "


LINKhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788438/
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities